A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma | MicrobiomeTrials
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2026-04-30Est. Completion: 2031-06
Enrollment target: 900 participants
Locations
Texas Oncology - Northeast Texas /ID# 280417, Tyler, Texas, United States
Tamworth Hospital /ID# 280099, North Tamworth, New South Wales, Australia
Prince Of Wales Hospital - Randwick /ID# 280085, Randwick, New South Wales, Australia
Monash Health - Monash Medical Centre - Clayton /ID# 280076, Clayton, Victoria, Australia
Fiona Stanley Hospital /ID# 280079, Murdoch, Western Australia, Australia
Tel Aviv Sourasky Medical Center /ID# 279414, Tel Aviv, Tel Aviv, Israel
Rambam Health Care Campus- Haifa /ID# 279409, Haifa, Israel
The Cancer Institute Hospital Of JFCR /ID# 280140, Koto-ku, Tokyo, Japan
China Medical University Hospital /ID# 279725, Taichung, Taiwan